Leukaemia DNA vaccine - Inovio/University of Southampton

Drug Profile

Leukaemia DNA vaccine - Inovio/University of Southampton

Alternative Names: p.DOM-WT1-126; p.DOM-WT1-37

Latest Information Update: 17 Jul 2013

Price : $50

At a glance

  • Originator University of Southampton
  • Developer Inovio Pharmaceuticals; University of Southampton
  • Class Cancer vaccines; DNA vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Acute myeloid leukaemia; Chronic myeloid leukaemia

Most Recent Events

  • 29 Jun 2013 Suspended - Phase-II for Chronic myeloid leukaemia in United Kingdom (IM)
  • 29 Jun 2013 Suspended - Phase-II for Acute myeloid leukaemia in United Kingdom (IM)
  • 07 Dec 2012 Inovio opens enrolment in a phase II trial for Acute myeloid leukaemia in United Kingdom
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top